Introduction {#ams2348-sec-0005}
============

Capillary refill time (CRT) has been widely adopted as a clinical assessment of circulatory status.[1](#ams2348-bib-0001){ref-type="ref"} Measuring CRT in emergency settings is beneficial for assessing disease severity in patients as testing is easy, rapid, and non‐invasive. However, data on the validity and reliability of CRT have been inconsistent,[2](#ams2348-bib-0002){ref-type="ref"}, [3](#ams2348-bib-0003){ref-type="ref"} and the main concerns include the lack of objectivity (e.g., time measurements are not automated) and dependence on visual assessments by examiners.[2](#ams2348-bib-0002){ref-type="ref"}, [3](#ams2348-bib-0003){ref-type="ref"}

To overcome these limitations, we previously developed quantitative CRT (Q‐CRT).[4](#ams2348-bib-0004){ref-type="ref"} In that pilot study, we found a positive association between longer Q‐CRT and higher lactate levels in 23 patients in the intensive care unit.[4](#ams2348-bib-0004){ref-type="ref"} However, we did not show a linear relationship between an index of circulatory status and patient outcome variables in the emergency department. Also, a larger sample size was needed to reach adequate statistical power. We were able to measure transmitted light quantity through Q‐CRT; measuring transmitted light quantity might be more stable and objective than Q‐CRT itself because the former minimizes bias.

The purpose of this study was to introduce a quantitative and clinically applicable index of circulatory status that can be measured using Q‐CRT. We also carried out a prospective study to evaluate the linear association between Q‐CRT, the index of circulatory status, and lactate levels in a patient sample with sufficient statistical power.

Materials and Methods {#ams2348-sec-0006}
=====================

Setting {#ams2348-sec-0007}
-------

This study was a prospective single‐center observational study undertaken at the Yokohama City University Hospital (Yokohama, Japan). The hospital\'s catchment area is the southern area of Yokohama City, which had an estimated population of 3.7 million in 2017.

Design {#ams2348-sec-0008}
------

This study design was an observational prospective study, and no sample size calculation was carried out because it was an explanatory study. The study was approved by the Institutional Review Board of Yokohama City University. All patients gave informed consent to participate in the study.

Patients {#ams2348-sec-0009}
--------

Of 1,399 outpatients in our hospital\'s emergency department from November 2015 to July 2016, we were able to measure Q‐CRT in 168 patients (12%) because we used only a single Q‐CRT measuring device in the department. The emergency department consisted of two emergency physicians, a cardiologist, a respirologist, a gastroenterologist, an orthopedist, and a neurosurgeon, with only one of seven physicians working during the night shift. When either of the emergency physicians worked, we measured Q‐CRT. We excluded trauma patients, patients undergoing dialysis, and those with missing blood laboratory test data (*n* = 29). After applying these criteria, 139 patients with endogenous diseases were eligible for this study.

Measurement of quantitative capillary refill time and ∆*A* ~b~ {#ams2348-sec-0010}
--------------------------------------------------------------

Figure [1](#ams2348-fig-0001){ref-type="fig"} shows wearing of the apparatus for measuring Q‐CRT, Figure [2](#ams2348-fig-0002){ref-type="fig"} depicts the schema of Q‐CRT measurements. Transmitted light quantity measured by a pulse oximeter equipped with an SpO~2~ sensor is related to blood volume, based on Lambert--Beer\'s law.[5](#ams2348-bib-0005){ref-type="ref"} Mechanical pressure with 500 mmHg lasting 5 s is applied to the index finger. This stops blood flow, and transmitted light quantity increases. When the pressure is removed, blood flow restarts, and transmitted light quantity decreases. In our previous study, we defined Q‐CRT as the time in seconds from the release of the pressure to the time when the blood flow reached 90% of the original flow, which was measured for 5 s at the beginning of the test before applying pressure.

![Wearing of the apparatus for measuring quantitative capillary refill time. Put the apparatus on the finger with a pulse oximeter.](AMS2-5-321-g001){#ams2348-fig-0001}

![Schematic of quantitative capillary refill time measurements. Transmitted light quantity obtained by a pulse oximeter equipped with a hemoglobin saturation of oxygen sensor is related to blood volume, based on Lambert--Beer\'s law.[5](#ams2348-bib-0005){ref-type="ref"} Q‐CRT, quantitative capillary refill time.](AMS2-5-321-g002){#ams2348-fig-0002}

Transmitted light quantity (*A*) measured by a pulse oximeter is defined by subtracting the light quantity input value from the output value, which is equivalent to the amount of light absorbed into finger tissue, and blood flow. Transmitted light quantity is then obtained through the following equation, based on Lambert--Beer\'s law:[5](#ams2348-bib-0005){ref-type="ref"} $$A \equiv \text{log}\left( \frac{L_{in}}{L_{out}} \right) = A_{b} + A_{t} = E_{b} \times H_{b} \times D_{b} + Z_{t} \times D_{t},$$

where *L* ~in~ is incident light intensity, *L* ~out~ is transmitted light intensity, *A* ~b~ is the degree of dimming by blood, *A* ~t~ is the degree of dimming by tissue without blood, *E* ~b~ is the absorptivity coefficient (dL/g\*cm) of blood, *H* ~b~ is hemoglobin density (g/dL), *D* ~b~ is the thickness of tissue with blood flow (cm), *Z* ~t~ is the rate of the degree of dimming by tissue without blood, and *D* ~t~ is the thickness of tissue without blood (cm).

Transmitted light quantity through compression equals dimmed light quantity through absorption into the tissue and reduced blood thickness: $$A_{comp} = \text{log}\left( \frac{L_{in}}{L_{{out}_{comp}}} \right) = A_{t_{comp}} = Z_{t} \times D_{t_{comp}},$$

where *A* ~comp~ is transmitted light quantity when compressed, $L_{{out}_{comp}}$ is transmitted light intensity when compressed, $A_{t_{comp}}$ is transmitted light quantity through tissue without blood when compressed, and $D_{t_{comp}}$ is the thickness of tissue without blood when compressed (cm).

Subtracting equation [(2)](#ams2348-disp-0002){ref-type="disp-formula"} from equation [(1)](#ams2348-disp-0001){ref-type="disp-formula"} provides equation [(3)](#ams2348-disp-0003){ref-type="disp-formula"}, which measures changes in transmitted light quantity by compression and also represents the sum of the degree of dimming through blood and tissue without blood: $$A - A_{comp} = \text{log}\left( \frac{L_{{out}_{comp}}}{L_{out}} \right) = A_{b} + {(A_{t} - A_{t_{comp}})} = E_{b} \times H_{b} \times D_{b} + Z_{t} \times {(D_{t} - D_{t_{comp}})}.$$

Because the pulse oximeter uses both red and infrared light, equations [(1)](#ams2348-disp-0001){ref-type="disp-formula"} and [(2)](#ams2348-disp-0002){ref-type="disp-formula"} can be expressed as: $$\begin{array}{cl}
A_{R} & {= \text{log}\left( \frac{L_{{out}_{{comp}\, R}}}{L_{{out}_{R}}} \right) = A_{b_{R}} + {(A_{t} - A_{t_{comp}})}_{R}} \\
 & {= E_{b_{R}} \times H_{b} \times D_{b} + Z_{t_{R}} \times {(D_{t} - D_{t_{comp}})},} \\
\end{array}$$ $$\begin{array}{cl}
{A_{IR} =} & {\text{log}\left( \frac{L_{{out}_{{comp}\,{IR}}}}{L_{{out}_{IR}}} \right) = A_{b_{IR}} + {(A_{t} - At_{comp})}_{IR}} \\
 & {= E_{b_{IR}} \times H_{b} \times D_{b} + Z_{t_{IR}} \times {(D_{t} - D_{t_{comp}})}.} \\
\end{array}$$

where R denotes all indices and values obtained under red light and IR denotes all indices and values obtained under infrared light.

In equations [(4)](#ams2348-disp-0004){ref-type="disp-formula"} and [(5)](#ams2348-disp-0005){ref-type="disp-formula"}, $Z_{t_{R}}$ is considered equal to $Z_{t_{IR}}$. The quantity of light dimmed by blood only defines *∆A* ~b~ (delta *A* ~b~), which is the difference between the quantity of light dimmed under infrared light and that dimmed under red light. The index is calculated by subtracting equation [(4)](#ams2348-disp-0004){ref-type="disp-formula"} from equation [(5)](#ams2348-disp-0005){ref-type="disp-formula"} (Fig. [3](#ams2348-fig-0003){ref-type="fig"}):

![Calculation of the *∆A* ~b~ index of circulatory status. Dimmed light quantity by blood alone defines ∆*A* ~b~ (delta *A* ~b~), which is the difference between the degree of dimmed light under infrared light and under red light.](AMS2-5-321-g003){#ams2348-fig-0003}

$$\Delta A_{b} = A_{IR} - A_{R} = \text{log}\left( \frac{L_{{out}_{{comp}\,{IR}}}}{L_{{out}_{IR}}} \right) - \text{log}\left( \frac{L_{{out}_{{comp}\, R}}}{L_{{out}_{R}}} \right) = {(E_{b_{IR}} - E_{b_{R}})} \times H_{b} \times D_{b},$$

This equation shows *∆A* ~b~ equal to (IR absorption coefficient − R absorption coefficient) × hemoglobin density × tissue thickness with blood flow. *∆A* ~b~ is valid only for blood data.

Data collection and variables {#ams2348-sec-0011}
-----------------------------

We obtained data on the following patient characteristics and clinical information following arrival at the outpatient department: age (years), sex, body temperature (°C), systolic blood pressure (mmHg), heart rate (b.p.m.), respiratory rate (breaths/min), SpO~2~ (%), white blood cell count (×10^9^/L), hemoglobin (g/dL), albumin (g/dL), blood urea nitrogen (mg/dL), creatinine (mg/dL), C‐reactive protein (mg/dL), sodium (Na; mEq/L), potassium (K; mEq/L), chloride (Cl; mEq/L), Q‐CRT (s), and Δ*A* ~b~. We classified the main condition of a disease based on the International Statistical Classification of Diseases and Related Health Problems 10th Revision, version 2016, to classify patients as having the following conditions: "certain infectious and parasitic diseases", "neoplasms", "diseases of the blood and blood‐forming organs and certain disorders involving the immune mechanism", "endocrine, nutritional and metabolic diseases", "mental and behavioural disorders", "diseases of the nervous system", "diseases of the eye and adnexa", "diseases of the ear and mastoid process", "disease of the circulatory system", "diseases of the respiratory system", "diseases of the digestive system", "diseases of the skin and subcutaneous tissue", "disease of the musculoskeletal system and connective tissue", "diseases of the genitourinary system", "pregnancy, childbirth and the puerperium", "certain conditions originating in the perinatal period", "congenital malformations, deformations and chromosomal abnormalities", and "symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified", "injury, poisoning, and certain other consequences of external causes".

Venous lactic acid concentration (mmol/L) was used as the outcome variable. Based on the reference value for lactic acid, we adopted 2 mmol/L as the cut‐off value.[6](#ams2348-bib-0006){ref-type="ref"}, [7](#ams2348-bib-0007){ref-type="ref"}, [8](#ams2348-bib-0008){ref-type="ref"} We assigned patients with a lactic acid level ≥2 mmol/L to the high lactate group, and those with lactate level \<2 mmol/L to the normal lactate group.

Statistical analysis {#ams2348-sec-0012}
--------------------

First, to compare patient characteristics and laboratory data between the two groups, the Mann--Whitney *U*‐test and χ^2^‐test were used for continuous and categorical variables, respectively. Second, we categorized Δ*A* ~b~ into two groups based on the median value, as the value was expected to have an unknown distribution. Finally, we applied a multiple logistic regression model to test the association between Δ*A* ~b~ and the high lactate group. Covariates included patient characteristics and laboratory data. We also used the Hosmer--Lemeshow goodness‐of‐fit test to evaluate the validity of the regression model; *P* \> 0.05 indicated model adequacy.[9](#ams2348-bib-0009){ref-type="ref"} Stata version 13.1 (StataCorp, College Station, TX, USA) was used for all analyses, and a two‐tailed *P* \< 0.05 was considered statistically significant.

Results {#ams2348-sec-0013}
=======

Of the 139 eligible patients, 45 and 94 were classified to the high and normal lactate groups, respectively. Tables [1](#ams2348-tbl-0001){ref-type="table"} and [2](#ams2348-tbl-0002){ref-type="table"} show the results of the comparisons of patient characteristics and laboratory data between the high and normal lactate groups. Δ*A* ~b~ was significantly lower in the high lactate group (*P* \< 0.001). For both the high and normal lactate groups, we observed higher rates of patients having "certain infectious and parasitic diseases", "diseases of the respiratory system", and "diseases of the digestive system". However, no significant differences in the distribution of disease types were found between the two groups. We also found no significant associations between the other variables and the high lactate group.

###### 

Univariate associations between lactate levels and study variables among patients with endogenous diseases treated in an emergency department (*n* = 139)

                                                         \<2 mmol/L (*n* = 94)     ≥2 mmol/L (*n* = 45)      *P‐*value
  ------------------------------------------------------ ------------------------- ------------------------- -----------
  Age, years                                             55 (13--94)               60 (19--97)               0.181
  Gender, female[a](#ams2348-note-0002){ref-type="fn"}   49 (−40%)                 18 (−40%)                 0.181
  BT, °C                                                 36.5 (35.1--39.7)         36.5 (34.6--40.1)         0.446
  SBP, mmHg                                              133 (77--230)             143 (97--220)             0.185
  HR, b.p.m.                                             83 (45--136)              84 (51--144)              0.874
  RR, breaths/min                                        20 (12--38)               20 (12--40)               0.371
  SpO~2~, %                                              98 (78--100)              98 (86--100)              0.506
  Hb, g/dL                                               13.2 (7.1--16.5)          13.5 (6.6--16.2)          0.525
  WBC, /μL                                               7700 (2500--22 200)       7500 (4200--38 600)       0.389
  Alb, g/dL                                              4.1 (2.3--5.1)            4 (2.1--4.9)              0.716
  BUN, mg/dL                                             14 (5--61)                16 (7--74)                0.161
  Crea, mg/dL                                            0.73 (0.32--4.3)          0.74 (0.43--2.84)         0.412
  CRP, mg/dL                                             0.12 (0.01--24.4)         0.11 (0.01--46.70)        0.776
  Na, mEq/L                                              140 (133--144)            140 (128--146)            0.813
  K, mEq/L                                               3.8 (2.1--4.7)            3.8 (2.9--5.2)            0.679
  Cl, mEq/L                                              105 (97--112)             104 (86--110)             0.284
  Q‐CRT, s                                               1.82 (0.57--6.80)         2.32 (0.81--6.97)         0.053
  Δ*A* ~b~                                               0.053 (−0.022 to 0.150)   0.028 (−0.040 to 0.115)   \<0.001

Δ*A* ~b~, calculated index of circulatory status; Alb, albumin; BT, body temperature; BUN, blood urea nitrogen; Cl, chloride; Crea, creatinine; CRP, C‐reactive protein; Hb, hemoglobin; HR, heart rate; K, potassium; Na, sodium; Q‐CRT, quantitative capillary refill time; RR, respiratory rate; SBP, systolic blood pressure; SpO~2~, hemoglobin saturation; WBC, white blood cell.

Frequency (%); others represent: median (minimum--maximum).

John Wiley & Sons, Ltd

###### 

Lactate levels and disease type based on ICD‐10[a](#ams2348-note-0011){ref-type="fn"}

                                                                                                        normal lactate group (*n* = 94)   high lactate group (*n* = 45)        
  ----------------------------------------------------------------------------------------------------- --------------------------------- ------------------------------- ---- -----
  Certain infectious and parasitic diseases                                                             21                                22%                             4    9%
  Neoplasms                                                                                             0                                 0%                              1    2%
  Diseases of the blood and blood‐forming organs and certain disorders involving the immune mechanism   1                                 1%                              0    0%
  Endocrine, nutritional and metabolic diseases                                                         0                                 0%                              0    0%
  Mental and behavioral disorders                                                                       1                                 1%                              0    0%
  Diseases of the nervous system                                                                        7                                 7%                              2    4%
  Diseases of the eye and adnexa                                                                        0                                 0%                              0    0%
  Diseases of the ear and mastoid process                                                               4                                 4%                              4    9%
  Diseases of the circulatory system                                                                    6                                 6%                              4    9%
  Diseases of the respiratory system                                                                    12                                13%                             6    13%
  Diseases of the digestive system                                                                      16                                17%                             11   24%
  Diseases of the skin and subcutaneous tissue                                                          4                                 4%                              1    2%
  Diseases of the musculoskeletal system and connective tissue                                          6                                 6%                              1    2%
  Diseases of the genitourinary system                                                                  4                                 4%                              3    7%
  Pregnancy, childbirth and the puerperium                                                              0                                 0%                              0    0%
  Certain conditions originating in the perinatal period                                                0                                 0%                              0    0%
  Congenital malformations, deformations and chromosomal abnormalities                                  0                                 0%                              0    0%
  Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified              7                                 7%                              4    9%
  Injury, poisoning, and certain other consequences of external causes                                  5                                 5%                              4    9%

Fisher\'s exact test: *P* = 0.627

John Wiley & Sons, Ltd

Δ*A* ~b~ was not normally distributed; therefore, we used the median Δ*A* ~b~ value of 0.0445 as the cut‐off for further analysis. In the multivariate analysis, we considered the model adequately fitted the data, as the Hosmer--Lemeshow goodness‐of‐fit test result was not significant (*P* = 0.972). After controlling for all other variables, Δ*A* ~b~ was independently and significantly associated with the high lactate group (odds ratio \[95% confidence interval\], 0.16 \[0.05--0.45\]; Table [3](#ams2348-tbl-0003){ref-type="table"}). The Na and Cl concentrations were also independently associated with the high lactate group (*P* = 0.049 and 0.030, respectively).

###### 

Association between higher severity and calculated index of circulatory status (Δ*A* ~b~) based on multivariate analysis among patients with endogenous diseases treated in an emergency department (*n* = 139)

                                                                          Odds ratio                  (95% CI)   *P*‐value      
  ----------------------------------------------------------------------- --------------------------- ---------- -------------- -------
  Age                                                                                                 1.01       (0.99--1.04)   0.353
  Gender                                                                  (0, female; 1, male)        1.53       (0.57--4.11)   0.404
  BT                                                                                                  0.74       (0.45--1.19)   0.211
  SBP                                                                                                 1.01       (0.99--1.03)   0.328
  HR                                                                                                  1.02       (0.99--1.05)   0.159
  RR                                                                                                  1.06       (0.98--1.16)   0.158
  SpO~2~                                                                                              1.15       (0.93--1.42)   0.208
  Hb                                                                                                  1.11       (0.80--1.55)   0.528
  WBC                                                                                                 1.00       (1.00--1.00)   0.622
  Alb                                                                                                 1.14       (0.31--4.25)   0.846
  BUN                                                                                                 1.02       (0.94--1.11)   0.631
  Crea                                                                                                1.37       (0.23--8.09)   0.726
  CRP                                                                                                 0.99       (0.88--1.12)   0.908
  Na                                                                                                  1.28       (1.00--1.63)   0.049
  K                                                                                                   1.39       (0.47--4.13)   0.557
  Cl                                                                                                  0.81       (0.67--0.98)   0.03
  Δ*A* ~b~                                                                (0, \<0.0445; 1, ≥0.0445)   0.16       (0.05--0.45)   0.001
  Hosmer--Lemeshow goodness‐of‐fit test (χ^2^‐test value \[*P*‐value\])   2.25                        −0.972                    

ΔAb, calculated index of circulatory status; Alb, albumin; BT, body temperature; BUN, blood urea nitrogen; CI, confidence interval; Crea, creatinine; Cl, chloride; CRP, C‐reactive protein; Hb, hemoglobin; HR, heart rate; K, potassium; Na, sodium; RR, respiratory rate; SBP, systolic blood pressure; SpO~2~, hemoglobin saturation; WBC, white blood cell.

John Wiley & Sons, Ltd

Discussion {#ams2348-sec-0014}
==========

In this study, we devised Δ*A* ~b~, based on our previous study on Q‐CRT, as an index of high lactate to overcome the shortcomings of CRT. In both univariate and multivariate analyses, a lower Δ*A* ~b~, indicating lower blood flow, was independently and significantly associated with the high lactate group. Our findings have clinical implications because we showed that Δ*A* ~b~ is a feasible, non‐invasive, and rapid assessment method for high lactate in patients being examined in emergency primary care settings. A lower Δ*A* ~b~ indicates poor blood flow, and this allows physicians to immediately prepare for necessary treatments. The use of Δ*A* ~b~ for triage in the emergency department might help in the early detection of ill patients.

Δ*A* ~b~ values could predict a patient\'s lactate level, for which a cut‐off of 2 mmol/L was used in this study. Survivors among patients with shock showed a decrease in lactic acid levels of 10% per hour after the beginning of treatment.[10](#ams2348-bib-0010){ref-type="ref"} Also, survival in patients with sepsis was associated with early lactate normalization, defined as a decline to \<2.0 mmol/L during the first 6 h of resuscitation or \>50% lactate clearance, defined by dividing the difference between the initial lactic level and the level after 6 h by the initial level.[11](#ams2348-bib-0011){ref-type="ref"} Our finding of a significant association between a lower Δ*A* ~b~ and a lactic acid level \>2 mmol/L indicates that Δ*A* ~b~ could be an adequate surrogate marker for high lactate.

There are four potential mechanisms associated with a decrease in Δ*A* ~b~, based on equation [(6)](#ams2348-disp-0006){ref-type="disp-formula"}. First, decreased oxidation might be related to a lower Δ*A* ~b~. A decline in oxidized hemoglobin and oxygen saturation could cause a decreased absorptivity coefficient (*E*), which would then contribute to a lower Δ*A* ~b~. Second, reduced hemoglobin and increased methemoglobin and carboxyhemoglobin levels could increase absorptivity coefficients, resulting in a lower Δ*A* ~b~. Third, anemia and bleeding likely cause decreased hemoglobin levels, which again may result in a lower Δ*A* ~b~. Finally, shock, strong and sharp pain, or hypothermia under certain conditions can cause decreased peripheral circulation blood volume and constricted peripheral arteries, causing lower Δ*A* ~b~.[12](#ams2348-bib-0012){ref-type="ref"}, [13](#ams2348-bib-0013){ref-type="ref"}, [14](#ams2348-bib-0014){ref-type="ref"} Therefore, Δ*A* ~b~ could indicate the level of oxygen saturation and blood flow in a patient.

The Na and Cl concentrations were also independently associated with high lactate. High Na might result from dehydration,[15](#ams2348-bib-0015){ref-type="ref"} leading to high lactate levels, and low Cl might result from metabolic alkalosis,[16](#ams2348-bib-0016){ref-type="ref"} leading to high lactate levels.

Limitations {#ams2348-sec-0015}
===========

This study has several limitations. First, the lactic acid level (the outcome in our study) was measured in peripheral venous blood. Venous and arterial blood might show inconsistent lactic acid levels, pH, bicarbonate, and base excess in a blood gas analysis.[17](#ams2348-bib-0017){ref-type="ref"}, [18](#ams2348-bib-0018){ref-type="ref"}, [19](#ams2348-bib-0019){ref-type="ref"}, [20](#ams2348-bib-0020){ref-type="ref"} However, venous and arterial lactate acid levels were both significantly associated with poor outcomes in patients with shock.[21](#ams2348-bib-0021){ref-type="ref"} Second, we did not measure the tourniquet time and elapsed time, and the time until drawing blood after the Q‐CRT and Δ*A* ~b~ measurement. Potentially unequal timing of these measurements might have caused differences in Q‐CRT and Δ*A* ~b~. However, as procedures in emergency outpatient departments are carried out systematically, a stable environment for measuring Q‐CRT would be provided. Third, patient characteristics and disease stages might have varied in our sample, although the distribution of diseases was not statistically different between the two groups. Fourth, we could not establish a causal relationship between Δ*A* ~b~ and lactic acid levels as this was an observational study. Fifth, we were only able to measure Q‐CRT in 12% of all outpatients in our department and measured by only emergency physicians. Even though the analyzed patients represented mostly day‐time outpatients, this low percentage might limit applying our findings to other facilities. Finally, this was a single‐center study; therefore, our findings might not apply to patients in other facilities and other regions, and might not be generalizable.

Conclusion {#ams2348-sec-0016}
==========

In conclusion, in this study, we introduced Δ*A* ~b~, as assessed through Q‐CRT, as an index of lactate levels to overcome the shortcomings of Q‐CRT. We show that Δ*A* ~b~ is a feasible, non‐invasive, and rapid assessment of lactate levels in emergency primary care settings. Future multicenter studies with a longitudinal design are needed to verify our findings.
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